These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36028587)

  • 1. Considerations in the Immunogenicity Assessment Strategy for Oligonucleotide Therapeutics (ONTs).
    Bano N; Ehlinger C; Yang TY; Swanson M; Allen S
    AAPS J; 2022 Aug; 24(5):93. PubMed ID: 36028587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Considerations of the Japanese Research Working Group for the ICH S6 & Related Issues Regarding Nonclinical Safety Assessments of Oligonucleotide Therapeutics: Comparison with Those of Biopharmaceuticals.
    Hirabayashi Y; Maki K; Kinoshita K; Nakazawa T; Obika S; Naota M; Watanabe K; Suzuki M; Arato T; Fujisaka A; Fueki O; Ito K; Onodera H
    Nucleic Acid Ther; 2021 Apr; 31(2):114-125. PubMed ID: 33470890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leveraging microphysiological systems to address challenges encountered during development of oligonucleotide therapeutics.
    Ramsden D; Belair DG; Agarwal S; Andersson P; Humphreys S; Dalmas DA; Stahl SH; Maclauchlin C; Cichocki JA
    ALTEX; 2022; 39(2):273–296. PubMed ID: 34766620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the Immunogenicity Potential for Oligonucleotide-Based Drugs.
    Henry SP; Arfvidsson C; Arrington J; Canadi J; Crowe D; Gupta S; Lohmann S; Massonnet B; Mytych D; Rogers T; Rogers H; Stebbins C; Stovold C; Verthelyi D; Vigil A; Xuan C; Xu Y; Yu R; Klem T
    Nucleic Acid Ther; 2022 Oct; 32(5):369-377. PubMed ID: 36178478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scientific Review of the Proarrhythmic Risks of Oligonucleotide Therapeutics: Are Dedicated ICH S7B/E14 Studies Needed for Low-Risk Modalities?
    Qu Y; Henderson KA; Harper TA; Vargas HM
    Clin Pharmacol Ther; 2024 Jul; 116(1):96-105. PubMed ID: 38362953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics.
    Gorovits B; Wakshull E; Pillutla R; Xu Y; Manning MS; Goyal J
    J Immunol Methods; 2014 Jun; 408():1-12. PubMed ID: 24861938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges.
    van Brummelen EM; Ros W; Wolbink G; Beijnen JH; Schellens JH
    Oncologist; 2016 Oct; 21(10):1260-1268. PubMed ID: 27440064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Promising Therapeutic Potential of Oligonucleotides for Pulmonary Fibrotic Diseases.
    Paul D; Miller MH; Born J; Samaddar S; Ni H; Avila H; Krishnamurthy VR; Thirunavukkarasu K
    Expert Opin Drug Discov; 2023 Feb; 18(2):193-206. PubMed ID: 36562410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An innovative method for characterizing neutralizing antibodies against antibody-derived therapeutics.
    Coddens A; Snoeck V; Bontinck L; Buyse MA; Pine SO
    J Immunol Methods; 2020 Dec; 487():112896. PubMed ID: 33065122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An immunoinhibition approach to overcome the impact of pre-existing antibodies on cut point establishment for immunogenicity assessment of moxetumomab pasudotox.
    Schneider AK; Vainshtein I; Roskos LK; Chavez C; Sun B; Liang M
    J Immunol Methods; 2016 Aug; 435():68-76. PubMed ID: 27220271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralization Activity of Anti-drug Antibodies Against a Biotherapeutic Can Be Predicted from a Comprehensive Pharmacokinetics, Pharmacodynamics, and Anti-drug Antibody Data Analysis.
    Xu W; Maas B; Roadcap B; Swarup A; Steinmetz T; Luo L; Ichetovkin M; Wood S; Vazvaei-Smith F; Lee AW; Vora K; Helmy R
    AAPS J; 2022 Sep; 24(6):102. PubMed ID: 36167856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy.
    Chirmule N; Jawa V; Meibohm B
    AAPS J; 2012 Jun; 14(2):296-302. PubMed ID: 22407289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes.
    Krishna M; Nadler SG
    Front Immunol; 2016; 7():21. PubMed ID: 26870037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of immunogenicity on therapeutic antibody pharmacokinetics: A preclinical evaluation of the effect of immune complex formation and antibody effector function on clearance.
    Opolka-Hoffmann E; Jordan G; Otteneder M; Kieferle R; Lechmann M; Winter G; Staack RF
    MAbs; 2021; 13(1):1995929. PubMed ID: 34763611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reporting, Visualization, and Modeling of Immunogenicity Data to Assess Its Impact on Pharmacokinetics, Efficacy, and Safety of Monoclonal Antibodies.
    Passey C; Suryawanshi S; Sanghavi K; Gupta M
    AAPS J; 2018 Feb; 20(2):35. PubMed ID: 29484520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating and Reporting the Immunogenicity Impacts for Biological Products--a Clinical Pharmacology Perspective.
    Wang YM; Wang J; Hon YY; Zhou L; Fang L; Ahn HY
    AAPS J; 2016 Mar; 18(2):395-403. PubMed ID: 26721560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug Target Interference in Immunogenicity Assays: Recommendations and Mitigation Strategies.
    Zhong ZD; Clements-Egan A; Gorovits B; Maia M; Sumner G; Theobald V; Wu Y; Rajadhyaksha M
    AAPS J; 2017 Nov; 19(6):1564-1575. PubMed ID: 29063411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals.
    Gunn GR; Sealey DC; Jamali F; Meibohm B; Ghosh S; Shankar G
    Clin Exp Immunol; 2016 May; 184(2):137-46. PubMed ID: 26597698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of drug specific circulating immune complexes from in vivo cynomolgus monkey serum samples.
    Pierog P; Krishna M; Yamniuk A; Chauhan A; DeSilva B
    J Immunol Methods; 2015 Jan; 416():124-36. PubMed ID: 25462536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A breakthrough novel method to resolve the drug and target interference problem in immunogenicity assays.
    Zoghbi J; Xu Y; Grabert R; Theobald V; Richards S
    J Immunol Methods; 2015 Nov; 426():62-9. PubMed ID: 26255760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.